Our portfolio
Visterra

Effectively engineered biological therapeutics

Visterra, a biotechnology company, uses its proprietary platform to identify unique disease tangents, and design and engineer effective biological therapeutics.
Website
  • Domain
    Life Sciences
  • Investment type
    Direct equity
  • Status
    Exit
  • Initial investment
    Series C
  • Partnered in
    2012
  • Investment lead
    David Rossow
  • Headquarters
    USA
  • Program strategy
    Discovery & Translational Sciences
Portfolio news
In 2018, Visterra was acquired by Otsuka Pharmaceutical

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.